RESUMEN
Traumatic brain injury (TBI) causes acute and subacute tissue damage, but is also associated with chronic inflammation and progressive loss of brain tissue months and years after the initial event. The trigger and the subsequent molecular mechanisms causing chronic brain injury after TBI are not well understood. The aim of the current study was therefore to investigate the hypothesis that necroptosis, a form a programmed cell death mediated by the interaction of Receptor Interacting Protein Kinases (RIPK) 1 and 3, is involved in this process. Neuron-specific RIPK1- or RIPK3-deficient mice and their wild-type littermates were subjected to experimental TBI by controlled cortical impact. Posttraumatic brain damage and functional outcome were assessed longitudinally by repetitive magnetic resonance imaging (MRI) and behavioral tests (beam walk, Barnes maze, and tail suspension), respectively, for up to three months after injury. Thereafter, brains were investigated by immunohistochemistry for the necroptotic marker phosphorylated mixed lineage kinase like protein(pMLKL) and activation of astrocytes and microglia. WT mice showed progressive chronic brain damage in cortex and hippocampus and increased levels of pMLKL after TBI. Chronic brain damage occurred almost exclusively in areas with iron deposits and was significantly reduced in RIPK1- or RIPK3-deficient mice by up to 80%. Neuroprotection was accompanied by a reduction of astrocyte and microglia activation and improved memory function. The data of the current study suggest that progressive chronic brain damage and cognitive decline after TBI depend on the expression of RIPK1/3 in neurons. Hence, inhibition of necroptosis signaling may represent a novel therapeutic target for the prevention of chronic post-traumatic brain damage.
Asunto(s)
Astrocitos/metabolismo , Lesiones Traumáticas del Encéfalo/genética , Encéfalo/metabolismo , Microglía/metabolismo , Necroptosis/genética , Neuronas/metabolismo , Proteína Serina-Treonina Quinasas de Interacción con Receptores/genética , Animales , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Lesiones Traumáticas del Encéfalo/metabolismo , Lesiones Traumáticas del Encéfalo/patología , Lesiones Traumáticas del Encéfalo/fisiopatología , Lesión Encefálica Crónica/genética , Lesión Encefálica Crónica/metabolismo , Lesión Encefálica Crónica/patología , Lesión Encefálica Crónica/fisiopatología , Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Suspensión Trasera , Hipocampo/diagnóstico por imagen , Hipocampo/metabolismo , Hipocampo/patología , Imagen por Resonancia Magnética , Aprendizaje por Laberinto , Memoria , Ratones , Ratones Noqueados , Neuronas/patología , Proteínas Quinasas/metabolismoRESUMEN
Activation of the complement system propagates neuroinflammation and brain damage early and chronically after traumatic brain injury (TBI). The complement system is complex and comprises more than 50 components, many of which remain to be characterized in the normal and injured brain. Moreover, complement therapeutic studies have focused on a limited number of histopathological outcomes, which while informative, do not assess the effect of complement inhibition on neuroprotection and inflammation in a comprehensive manner. Using high throughput gene expression technology (NanoString), we simultaneously analyzed complement gene expression profiles with other neuroinflammatory pathway genes at different time points after TBI. We additionally assessed the effects of complement inhibition on neuropathological processes. Analyses of neuroinflammatory genes were performed at days 3, 7, and 28 post injury in male C57BL/6 mice following a controlled cortical impact injury. We also characterized the expression of 59 complement genes at similar time points, and also at 1- and 2-years post injury. Overall, TBI upregulated the expression of markers of astrogliosis, immune cell activation, and cellular stress, and downregulated the expression of neuronal and synaptic markers from day 3 through 28 post injury. Moreover, TBI upregulated gene expression across most complement activation and effector pathways, with an early emphasis on classical pathway genes and with continued upregulation of C2, C3 and C4 expression 2 years post injury. Treatment using the targeted complement inhibitor, CR2-Crry, significantly ameliorated TBI-induced transcriptomic changes at all time points. Nevertheless, some immune and synaptic genes remained dysregulated with CR2-Crry treatment, suggesting adjuvant anti-inflammatory and neurotropic therapy may confer additional neuroprotection. In addition to characterizing complement gene expression in the normal and aging brain, our results demonstrate broad and chronic dysregulation of the complement system after TBI, and strengthen the view that the complement system is an attractive target for TBI therapy.
Asunto(s)
Lesiones Traumáticas del Encéfalo/genética , Lesión Encefálica Crónica/genética , Encéfalo/efectos de los fármacos , Activación de Complemento/genética , Enfermedades Neuroinflamatorias/genética , Animales , Encéfalo/inmunología , Encéfalo/metabolismo , Encéfalo/patología , Lesiones Traumáticas del Encéfalo/inmunología , Lesiones Traumáticas del Encéfalo/patología , Lesión Encefálica Crónica/inmunología , Lesión Encefálica Crónica/patología , Activación de Complemento/inmunología , Complemento C2/genética , Complemento C2/inmunología , Complemento C3/antagonistas & inhibidores , Complemento C3/genética , Complemento C3/inmunología , Complemento C4/genética , Complemento C4/inmunología , Inactivadores del Complemento/farmacología , Perfilación de la Expresión Génica , Ratones , Enfermedades Neuroinflamatorias/inmunología , Proteínas Recombinantes de Fusión/farmacología , TranscriptomaRESUMEN
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disorder linked to repetitive traumatic brain injury (TBI) and characterized by deposition of hyperphosphorylated tau at the depths of sulci. We sought to determine the presence of CTE pathology in a brain bank for neurodegenerative disorders for individuals with and without a history of contact sports participation. Available medical records of 1721 men were reviewed for evidence of past history of injury or participation in contact sports. Subsequently, cerebral cortical samples were processed for tau immunohistochemistry in cases with a documented history of sports exposure as well as age- and disease-matched men and women without such exposure. For cases with available frozen tissue, genetic analysis was performed for variants in APOE, MAPT, and TMEM106B. Immunohistochemistry revealed 21 of 66 former athletes had cortical tau pathology consistent with CTE. CTE pathology was not detected in 198 individuals without exposure to contact sports, including 33 individuals with documented single-incident TBI sustained from falls, motor vehicle accidents, domestic violence, or assaults. Among those exposed to contact sports, those with CTE pathology did not differ from those without CTE pathology with respect to noted clinicopathologic features. There were no significant differences in genetic variants for those with CTE pathology, but we observed a slight increase in MAPT H1 haplotype, and there tended to be fewer homozygous carriers of the protective TMEM106B rs3173615 minor allele in those with sports exposure and CTE pathology compared to those without CTE pathology. In conclusion, this study has identified a small, yet significant, subset of individuals with neurodegenerative disorders and concomitant CTE pathology. CTE pathology was only detected in individuals with documented participation in contact sports. Exposure to contact sports was the greatest risk factor for CTE pathology. Future studies addressing clinical correlates of CTE pathology are needed.
Asunto(s)
Lesión Encefálica Crónica/etiología , Lesión Encefálica Crónica/patología , Encéfalo/patología , Enfermedades Neurodegenerativas/etiología , Enfermedades Neurodegenerativas/patología , Anciano , Apolipoproteínas E/genética , Traumatismos en Atletas/complicaciones , Traumatismos en Atletas/genética , Traumatismos en Atletas/metabolismo , Traumatismos en Atletas/patología , Encéfalo/metabolismo , Lesión Encefálica Crónica/genética , Lesión Encefálica Crónica/metabolismo , Femenino , Humanos , Inmunohistoquímica , Masculino , Proteínas de la Membrana/genética , Proteínas del Tejido Nervioso/genética , Enfermedades Neurodegenerativas/genética , Enfermedades Neurodegenerativas/metabolismo , Estudios Retrospectivos , Bancos de Tejidos , Proteínas tau/genética , Proteínas tau/metabolismoRESUMEN
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive mild traumatic brain injury. It is defined pathologically by the abnormal accumulation of tau in a unique pattern that is distinct from other tauopathies, including Alzheimer's disease (AD). Although trauma has been suggested to increase amyloid ß peptide (Aß) levels, the extent of Aß deposition in CTE has not been thoroughly characterized. We studied a heterogeneous cohort of deceased athletes and military veterans with neuropathologically diagnosed CTE (n = 114, mean age at death = 60) to test the hypothesis that Aß deposition is altered in CTE and associated with more severe pathology and worse clinical outcomes. We found that Aß deposition, either as diffuse or neuritic plaques, was present in 52 % of CTE subjects. Moreover, Aß deposition in CTE occurred at an accelerated rate and with altered dynamics in CTE compared to a normal aging population (OR = 3.8, p < 0.001). We also found a clear pathological and clinical dichotomy between those CTE cases with Aß plaques and those without. Aß deposition was significantly associated with the presence of the APOE ε4 allele (p = 0.035), older age at symptom onset (p < 0.001), and older age at death (p < 0.001). In addition, when controlling for age, neuritic plaques were significantly associated with increased CTE tauopathy stage (ß = 2.43, p = 0.018), co-morbid Lewy body disease (OR = 5.01, p = 0.009), and dementia (OR = 4.45, p = 0.012). A subset of subjects met the diagnostic criteria for both CTE and AD, and in these subjects both Aß plaques and total levels of Aß1-40 were increased at the depths of the cortical sulcus compared to the gyral crests. Overall, these findings suggest that Aß deposition is altered and accelerated in a cohort of CTE subjects compared to normal aging and that Aß is associated with both pathological and clinical progression of CTE independent of age.
Asunto(s)
Péptidos beta-Amiloides/metabolismo , Lesión Encefálica Crónica/patología , Encéfalo/patología , Enfermedades Neurodegenerativas/patología , Proteínas tau/metabolismo , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Apolipoproteína E4/genética , Atletas , Traumatismos en Atletas/epidemiología , Traumatismos en Atletas/genética , Traumatismos en Atletas/metabolismo , Traumatismos en Atletas/patología , Encéfalo/metabolismo , Lesión Encefálica Crónica/epidemiología , Lesión Encefálica Crónica/genética , Lesión Encefálica Crónica/metabolismo , Estudios de Cohortes , Comorbilidad , Humanos , Persona de Mediana Edad , Enfermedades Neurodegenerativas/epidemiología , Enfermedades Neurodegenerativas/genética , Enfermedades Neurodegenerativas/metabolismo , Placa Amiloide/etiología , Placa Amiloide/metabolismo , Placa Amiloide/patología , Índice de Severidad de la Enfermedad , Veteranos , Heridas Relacionadas con la Guerra/epidemiología , Heridas Relacionadas con la Guerra/genética , Heridas Relacionadas con la Guerra/metabolismo , Heridas Relacionadas con la Guerra/patologíaRESUMEN
We report the case of a 75-year-old ex-professional boxer who developed diplopia and eye movement abnormalities in his 60's followed by memory impairment, low mood and recurrent falls. Examination shortly before death revealed hypomimia, dysarthria, vertical supranuclear gaze palsy and impaired postural reflexes. Pathological examination demonstrated 4-repeat tau neuronal and glial lesions, including tufted astrocytes, consistent with a diagnosis of progressive supranuclear palsy. In addition, neurofibrillary tangles composed of mixed 3-repeat and 4-repeat tau and astrocytic tangles in a distribution highly suggestive of chronic traumatic encephalopathy were observed together with limbic TDP-43 pathology. Possible mechanisms for the co-occurrence of these two tau pathologies are discussed.
Asunto(s)
Lesión Encefálica Crónica/complicaciones , Lesión Encefálica Crónica/patología , Parálisis Supranuclear Progresiva/complicaciones , Parálisis Supranuclear Progresiva/patología , Anciano , Lesión Encefálica Crónica/genética , Humanos , Péptidos y Proteínas de Señalización Intercelular , Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina , Masculino , Progranulinas , Proteínas Serina-Treonina Quinasas/genética , Parálisis Supranuclear Progresiva/genética , Proteínas tau/genéticaRESUMEN
Chronic traumatic encephalopathy (CTE, previously called punch drunk and dementia pugilistica) has a rich history in the medical literature in association with boxing, but has only recently been recognized with other contact sports, such as football and ice hockey, as well as with military blast injuries. CTE is thought to be a neurodegenerative disease associated with repeated concussive and subconcussive blows to the head. There is characteristic gross and microscopic pathology found in the brain, including frontal and temporal atrophy, axonal degeneration, and hyperphosphorylated tau and TAR DNA-binding protein 43 pathology. Clinically, there are characteristic progressive deficits in cognition (memory, executive dysfunction), behavior (explosivity, aggression), mood (depression, suicidality), and motor function (parkinsonism), which correlate with the anatomic distribution of brain pathology. While CTE shares clinical and neuropathological traits with other neurodegenerative diseases, the clinical syndrome and the neuropathology as a whole are distinct from other neurodegenerative diseases. Here we review the CTE literature to date. We also draw on the literature from mild traumatic brain injury and other neurodegenerative dementias, particularly when these studies provide guidance for future CTE research. We conclude by suggesting seven essential areas for future CTE research.
Asunto(s)
Lesión Encefálica Crónica/terapia , Animales , Biomarcadores , Boxeo/lesiones , Lesión Encefálica Crónica/complicaciones , Lesión Encefálica Crónica/diagnóstico , Lesión Encefálica Crónica/epidemiología , Lesión Encefálica Crónica/genética , Lesión Encefálica Crónica/patología , Lesión Encefálica Crónica/psicología , Humanos , Imagen por Resonancia Magnética , Neuroimagen , Pruebas Neuropsicológicas , Tomografía de Emisión de Positrones , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada por Rayos XRESUMEN
This review summarizes recent developments that have contributed to understand how adenosine receptors, particularly A2A receptors, modulate brain injury in various animal models of neurological disorders, including Parkinson's disease (PD), stroke, Huntington's disease (HD), multiple sclerosis, Alzheimer's disease (AD) and HIV-associated dementia. It is clear that extracellular adenosine acting at adenosine receptors influences the functional outcome in a broad spectrum of brain injuries, indicating that A2A Rs may modulate some general cellular processes to affect neuronal cells death. Pharmacological, neurochemical and molecular/genetic approaches to the complex actions of A2A receptors in different cellular elements suggest that A2A receptor activation can be detrimental or protective after brain insults, depending on the nature of brain injury and associated pathological conditions. An interesting concept that emerges from these studies is A2A R's ability to fine tune neuronal and glial functions to produce neuroprotective effects. While the data presented here clearly highlight the complexity of using adenosinergic agents therapeutically in PD and other neurodegenerative disorders and point out many areas for further inquiry, they also confirm that adenosine receptor ligands, particularly A2A receptor ligands, have many promising characteristics that encourage the pursuit of their therapeutic potential.
Asunto(s)
Adenosina/metabolismo , Encefalopatías/metabolismo , Encéfalo/metabolismo , Citoprotección/fisiología , Degeneración Nerviosa/metabolismo , Receptor de Adenosina A2A/metabolismo , Animales , Encéfalo/efectos de los fármacos , Encéfalo/fisiopatología , Encefalopatías/tratamiento farmacológico , Encefalopatías/genética , Lesión Encefálica Crónica/genética , Lesión Encefálica Crónica/metabolismo , Lesión Encefálica Crónica/fisiopatología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/genética , Citoprotección/efectos de los fármacos , Humanos , Degeneración Nerviosa/genética , Degeneración Nerviosa/fisiopatología , Fármacos Neuroprotectores/farmacologíaRESUMEN
Traumatic brain injury (TBI) frequently results in cerebrovascular lesions that may increase secondary damage and cause neuropsychological impairment. Previous studies suggest an association among the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE), cardiovascular disease, and cognitive performance. Clinical and experimental studies have demonstrated the beneficial effects of ACE inhibitor treatment on vascular injury, hypertension, brain ischemia, and cognitive functioning. In a sample of 73 moderate and severe TBI patients, the authors assessed whether cognitive sequelae differed in relation to the ACE I/D polymorphism. D allele carrier patients performed worse than those with I/I polymorphism on tests involving attention and processing speed. Findings suggest that the physiopathological changes associated with TBI may have greater consequences in ACE D allele carriers.
Asunto(s)
Elementos Alu/genética , Lesión Encefálica Crónica/genética , Pruebas Neuropsicológicas/estadística & datos numéricos , Peptidil-Dipeptidasa A/genética , Polimorfismo Genético/genética , Adolescente , Adulto , Anciano , Alelos , Lesión Encefálica Crónica/diagnóstico , Lesión Encefálica Crónica/psicología , Cromosomas Humanos Par 17 , Elementos Transponibles de ADN/genética , Femenino , Eliminación de Gen , Genotipo , Escala de Coma de Glasgow , Heterocigoto , Humanos , Masculino , Persona de Mediana Edad , Desempeño PsicomotorRESUMEN
The catalytic subunit of telomerase reverse transcriptase (TERT) protects dividing cells from replicative senescence in vitro. Here, we show that expression of TERT mRNA is induced in the ipsilateral cortical neurons after occlusion of the middle cerebral artery in adult mice. Transgenic mice that overexpress TERT showed significant resistance to ischemic brain injury. Among excitotoxicity, oxidative stress, and apoptosis comprising of routes of ischemic neuronal death, NMDA receptor-mediated excitotoxicity was reduced in forebrain cell cultures overexpressing TERT. NMDA-induced accumulation of cytosolic free Ca2+ ([Ca2+]c) was reduced in forebrain neurons from TERT transgenic mice, which was attributable to the rapid flow of [Ca2+]c into the mitochondria from the cytosol without change in Ca2+ influx and efflux through the plasma membrane. The present study provides evidence that TERT is inducible in postmitotic neurons after ischemic brain injury and prevents NMDA neurotoxicity through shift of the cytosolic free Ca2+ into the mitochondria, and thus plays a protective role in ameliorating ischemic neuronal cell death.
Asunto(s)
Lesión Encefálica Crónica/prevención & control , Isquemia Encefálica/terapia , N-Metilaspartato , Síndromes de Neurotoxicidad/prevención & control , Telomerasa/biosíntesis , Animales , Lesión Encefálica Crónica/inducido químicamente , Lesión Encefálica Crónica/genética , Isquemia Encefálica/genética , Calcio/metabolismo , Células Cultivadas , Técnicas de Cocultivo , Proteínas de Unión al ADN , Modelos Animales de Enfermedad , Agonistas de Aminoácidos Excitadores , Colorantes Fluorescentes , Regulación de la Expresión Génica , Hipoxia-Isquemia Encefálica/metabolismo , Hipoxia-Isquemia Encefálica/patología , Hipoxia-Isquemia Encefálica/prevención & control , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/genética , Ratones , Ratones Transgénicos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Neuroglía/citología , Neuronas/citología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Síndromes de Neurotoxicidad/etiología , Neurotoxinas , ARN Mensajero/biosíntesis , Telomerasa/genéticaRESUMEN
BACKGROUND: Existing evidence suggests that some patients who sustain a head injury suffer cognitive decline many years later, and that head injury and possession of the APOE epsilon 4 allele are each risk factors for Alzheimer's disease. OBJECTIVE: To determine whether late cognitive decline after head injury is more prevalent among carriers of APOE epsilon 4. METHODS: A database of head injured patients was used. Initial assessment was at the time of their injury, between 1968 and 1985, and outcome data at six months were available. Their ages at the time of injury ranged between 2 and 70 years. A cohort of 396 subjects was reassessed at a mean of 18 years later, with determination of APOE genotype and detailed neuropsychological testing. RESULTS: Judging by the Glasgow outcome scale, twice as many patients had deteriorated as improved between six months after injury and the late assessment; 22.2% of APOE epsilon 4 carriers had a good late outcome compared with 30.5% of non-carriers (95% confidence interval for the difference, -0.7% to 17.2%; p = 0.084). There were no clear differences between epsilon 4 carriers and non-carriers in detailed neuropsychological assessments. CONCLUSIONS: Although this study provides additional evidence that a late decline may occur after head injury, there was no clear relation to APOE genotype. Despite the follow up interval of 15 to 25 years, the cohort is still too young (mean age 42.1 years) to assess the risk of Alzheimer's disease.
Asunto(s)
Enfermedad de Alzheimer/genética , Apolipoproteínas E/genética , Lesión Encefálica Crónica/genética , Trastornos del Conocimiento/genética , Pruebas Neuropsicológicas , Adolescente , Adulto , Anciano , Enfermedad de Alzheimer/diagnóstico , Apolipoproteína E4 , Lesión Encefálica Crónica/diagnóstico , Niño , Preescolar , Trastornos del Conocimiento/diagnóstico , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Predisposición Genética a la Enfermedad/genética , Genotipo , Escala de Consecuencias de Glasgow , Humanos , Masculino , Persona de Mediana Edad , Factores de RiesgoAsunto(s)
Enfermedad de Alzheimer/genética , Lesión Encefálica Crónica/genética , Trastornos del Conocimiento/genética , Adulto , Anciano , Enfermedad de Alzheimer/diagnóstico , Apolipoproteína E4 , Apolipoproteínas E/genética , Lesión Encefálica Crónica/diagnóstico , Trastornos del Conocimiento/diagnóstico , Estudios de Seguimiento , Predisposición Genética a la Enfermedad/genética , Humanos , Persona de Mediana Edad , Pruebas NeuropsicológicasRESUMEN
OBJECTIVE: To determine whether the cognitive status of professional football players varies as a function of age and apolipoprotein E (APOE) genotype. METHODS: Fifty-three active players underwent APOE and neuropsychological assessments. Players were grouped according to age (proxy indicator of high/low exposure to contact) and the presence/absence of at least one copy of the epsilon4 allele. Outcome measures were overall cognitive performance and scores in cognitive domains. RESULTS: As a group, older players possessing APOE epsilon4 exhibited significantly lower cognitive test scores than did all other players studied, including non-epsilon4-possessing players and younger epsilon4-carriers. Measures of general cognitive functioning, information-processing speed and accuracy, and attention were related to poorer performance among the epsilon4-carrying players. In an analysis of variance model, the interaction between APOE genotype and age was significant (P = 0.004). As determined using linear regression, age accounted for 34% of the variance in the memory index among APOE epsilon4-possessing players but did not contribute significantly to variance among the non-epsilon4-possessing players. Older APOE epsilon4-carriers were significantly overrepresented among players whose scores indicated possible cognitive impairment, with the criterion of performing two or more standard deviations below the general normal values in a summary index of general cognitive functioning. CONCLUSION: Older professional football players who possessed the APOE epsilon4 allele scored lower on cognitive tests than did players without this allele or less experienced players of any genotype. The cognitive status of professional athletes with repeated exposure to head trauma may therefore be influenced by age, inherited factors such as APOE genotype, and cumulative exposure to contact.
Asunto(s)
Apolipoproteínas E/genética , Traumatismos en Atletas/diagnóstico , Lesión Encefálica Crónica/diagnóstico , Trastornos del Conocimiento/diagnóstico , Fútbol Americano/lesiones , Genotipo , Pruebas Neuropsicológicas , Adulto , Factores de Edad , Alelos , Apolipoproteína E4 , Traumatismos en Atletas/genética , Daño Encefálico Crónico/diagnóstico , Daño Encefálico Crónico/genética , Lesión Encefálica Crónica/genética , Trastornos del Conocimiento/genética , Tamización de Portadores Genéticos , Humanos , Masculino , Factores de RiesgoRESUMEN
Extracellular adenosine critically modulates ischemic brain injury, at least in part through activation of the A(1) adenosine receptor. However, the role played by the A(2A) receptor has been obscured by intrinsic limitations of A(2A) adenosinergic agents. To overcome these pharmacological limitations, we explored the consequences of deleting the A(2A) adenosine receptor on brain damage after transient focal ischemia. Cerebral morphology, as well as vascular and physiological measures (before, during, and after ischemia) did not differ between A(2A) receptor knock-out and wild-type littermates. The volume of cerebral infarction, as well as the associated neurological deficit induced by transient filament occlusion of the middle cerebral artery, were significantly attenuated in A(2A) receptor knock-out mice. This neuroprotective phenotype of A(2A) receptor-deficient mice was observed in different genetic backgrounds, confirming A(2A) receptor disruption as its cause. Together with complimentary pharmacological studies, these data suggest that A(2A) receptors play a prominent role in the development of ischemic injury within brain and demonstrate the potential for anatomical and functional neuroprotection against stroke by A(2A) receptor antagonists.